00:00We are an emerging biotech life sciences company advancing novel therapies for what we believe
00:08could be disruptive assets and we have been, I and the team, we have been in drug development
00:17for quite some time and we feel very fortunate that we are ahead of the curve inspired by
00:24leaders like Stefan Bunzel of Moderna, where we are using artificial intelligence and machine learning in
00:36making a capital efficient and time efficient drug development effort and improving patient outcomes.
00:44Dr. Bakari, can you explain to us how that actually works? Because I think a lot of people are used to the idea of AI in the
00:50context of pharma being used for drug discovery, less so when it comes to clinical trials. What exactly is the
00:57application? What's it doing?
00:59So we have partnered with Reliant AI, that is a generative AI company and using their robust model and our
01:14proprietary data where we can, in our phase two study, can utilize AI to number one, do dynamic site
01:25selections. Number two, we could do some pharmacodynamic informed patient stratification and also utilize some
01:38simulation models that could help us predict geographically where patient recruitment would be better than in other areas.
01:49We are getting ready to run a global trial in a novel study to prevent relapse of acute urinary retention patient,
01:57primarily due to enlarged prostate. And this is a global study covering 390 patients and the old-fashioned ways
02:08that are just cumbersome and costly. So we're very excited that we're breaking some new ground
02:16in this area and we find success in this first phase. We then hope that we can also use AI for
02:26adaptive clinical designs and also predict decision-grade data outcomes. So we really believe that we
02:37are leading the way in this effort. Doctor, I spend my day looking at stock charts and, you know, when I hear
02:46you talk about your research, your trials, your use of AI, it all sounds very positive. But when I look at the
02:52stock chart and see Medica shares down, look, one year, 63 percent, it makes me wonder what investors are
03:00missing here. What do you want to say to investors on Bloomberg? The biotech sector is, I think, largely impacted by a lot of
03:12macro environment. And in a micro-cap company, which is pre-revenue, we become the first victims of any time there are
03:23macro shifts. But patience is a virtue. We are investor operators. The insiders with myself in the lead have
03:33$18 million invested at $4. And we are very bullish. As we enter 2026 with a lot of phase two catalysts, we have an
03:45AI drug enabled strategy and we have regulatory optionality. So I think as we demonstrate execution in the first half of
03:57this year, the investors will reward us as they rewarded us at the end of first quarter of last year when we gave our
04:05interim analysis for our novel therapy for non-melanoma skin diseases, especially basal cell carcinoma.
04:13So
Comments